BioVaxys Technology Corp. C.BIOV

debt settlement of 300K is completed...... go biov

[Humanist]

BIOVAXYS ANNOUNCES COMPLETED DEBT SETTLEMENT
by @newswire on 14 Oct 2022, 08:00
     
VANCOUVER, British Columbia, Oct. 14, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC-QB: BVAXF) ("BioVaxys" or the "Company") announces that, further to its news release dated October 6, 2022, it has settled an aggregate of $300,000 in debt through the issuance of common shares issued at a deemed price of $0.15 per common share.
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trades on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
[phone]